noom glp 1 companion Noom's GLP-1 Receives Major Update to Prepare for New Expected Prescription Drug Use-Related Software (PDURS) Model Noom's GLP-1 Companion Receives Major

Recently, the Food and Drug Administration officially approved semaglutide for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate-to-advanced fibrosis

Background Some observational studies found that there is an epidemiological association between type 2 diabetes (T2D) and sleep apnea (SA) and glucose-lowering drugs may lower SA risk

Label with date and protein count

Beyond these frontrunners, the pipeline is expanding: Novo Nordisk filed for FDA approval of CagriSema in 2025, the first once-weekly combination of GLP1 and amylin analogue

Across the research so far: ~54% fewer alcohol-related events ~45% lower relapse 3050% lower odds of developing AUD

Flexible partnership structures may include